α<sub>v</sub>β<sub>6</sub>-Targeted Molecular PET/CT Imaging of the Lungs After SARS-CoV-2 Infection.
Where this comes from
- Record sourced from PubMed, PMID 32948681.
- Also identified by DOI 10.2967/jnumed.120.255364 and PMC identifier 8679627.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
The true impact and long-term damage to organs such as the lungs after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection remain to be determined. Noninvasive molecularly targeted imaging may play a critical role in aiding visualization and understanding of the systemic damage. We have identified α<sub>v</sub>β<sub>6</sub> as a molecular target; an epithelium-specific cell surface receptor that is low or undetectable in healthy adult epithelium but upregulated in select injured tissues, including fibrotic lung. Herein we report the first human PET/CT images using the integrin α<sub>v</sub>β<sub>6</sub>-binding peptide (<sup>18</sup>F-α<sub>v</sub>β<sub>6</sub>-BP) in a patient 2 mo after the acute phase of infection. Minimal uptake of <sup>18</sup>F-α<sub>v</sub>β<sub>6</sub>-BP was noted in normal lung parenchyma, with uptake being elevated in areas corresponding to opacities on CT. This case suggests that <sup>18</sup>F-α<sub>v</sub>β<sub>6</sub>-BP PET/CT is a promising noninvasive approach to identify the presence and potentially monitor the persistence and progression of lung damage.
Medical subject headings
- Antigens, Neoplasm
- COVID-19
- Integrins
- Lung
- Positron Emission Tomography Computed Tomography